Quintiles Transitional Holdings (Q) has been under a strong bear grip, hence the stock is down -2.31% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.52% in the past 1 week. The stock has risen by 0.85% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.51% in the past 4 weeks.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.12% and the fifty day Moving Average is 5.16%. Quintiles Transnational Holdings Inc. is up 13.48% in the last three month period. Year-to-Date the stock performance stands at 10.24%.
Quintiles Transitional Holdings (Q) : The highest level Quintiles Transitional Holdings (Q) is projected to reach is $88 for the short term and the lowest estimate is at $73. The consolidated price target from 10 rating analysts who initiate coverage on the stock is $81.4 and the possibility the share price can swing is $4.79.
Quintiles Transitional Holdings (NYSE:Q): stock turned positive on Friday. Though the stock opened at $75.64, the bulls momentum made the stock top out at $75.9 level for the day. The stock recorded a low of $75.145 and closed the trading day at $75.69, in the green by 0.01%. The total traded volume for the day was 581,588. The stock had closed at $75.68 in the previous days trading.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.